Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Deloitte
Boehringer Ingelheim
Cantor Fitzgerald
Accenture
Moodys
Merck
QuintilesIMS
Chubb

Generated: April 25, 2018

DrugPatentWatch Database Preview

PROHANCE MULTIPACK Drug Profile

« Back to Dashboard

When do Prohance Multipack patents expire, and what generic alternatives are available?

Prohance Multipack is a drug marketed by Bracco and is included in one NDA.

The generic ingredient in PROHANCE MULTIPACK is gadoteridol. One supplier is listed for this compound. Additional details are available on the gadoteridol profile page.
Drug patent expirations by year for PROHANCE MULTIPACK
Pharmacology for PROHANCE MULTIPACK
Synonyms for PROHANCE MULTIPACK
(+-)-(10-(2-Hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-))gadolinium
(10-(2-Hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato)gadolinium
[2,2',2''-{10-[2-(hydroxy-kappaO)propyl]-1,4,7,10-tetraazacyclododecane-1,4,7-triyl-kappa(4)N(1),N(4),N(7),N(10)}triacetato-kappaO(3-)]gadolinium
066G548
1,4,7,10-Tetraazacyclododecan-1,4,7-triacetic acid, 10-(2-hydroxypropyl)-, gadolinium complex
120066-54-8
AC1L1TS2
BC678010
CAS-120066-54-8
CCG-213206
CHEBI:31643
D01137
D0M1PL
DB00597
DO1137
DPNNNPAKRZOSMO-UHFFFAOYSA-K
DSSTox_CID_28588
DSSTox_GSID_48662
DSSTox_RID_82859
DTXSID2048662
gadolinium 2,2',2''-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate
Gadolinium-HP-D03A
Gadolinium-HP-Do 3A
Gadolinium-HP-DO3A
Gadolinium, (10-(2-(hydroxy-kappaO)propyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-kappaN1,kappaN4,kappaN7,kappaN10,kappaO1,kappaO4,kappaO7)-
Gadolinium, (10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato(3-)-N(sup 1),N(sup 4),N(sup 7),N(sup 10),O(sup 1),O(sup 4),O(sup 7),O(sup 10))-
gadolinium(3+) 2-[4,7-bis(carboxylatomethyl)-10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecan-1-yl]acetate
gadolinium(3+); 2-[4-(2-hydroxypropyl)-7,10-bis(2-oxido-2-oxoethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate
GADOTERIDOL
Gadoteridol (JAN/USP/INN)
Gadoteridol [USAN:INN:BAN:JAN]
Gadoteridolum
Gadoteridolum [INN-Latin]
GD-HP-DO 3A
Gd-HP-DO3A
Gd-HPDO3A
Gd(HP-DO3A)
HE300932
HMS3264D11
HSDB 7549
HY-B0933
LS-70971
MOLI001032
NCGC00182068-02
NCGC00182068-03
NCGC00182068-04
NSC-760055
NSC760055
Pharmakon1600-01503834
ProHance
Prohance (TN)
SCHEMBL1650466
SQ 32692
SQ-32692
Tox21_113025
Tox21_113025_1
Tox21_113128

US Patents and Regulatory Information for PROHANCE MULTIPACK

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bracco PROHANCE MULTIPACK gadoteridol INJECTABLE;INJECTION 021489-001 Oct 9, 2003 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for PROHANCE MULTIPACK

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bracco PROHANCE MULTIPACK gadoteridol INJECTABLE;INJECTION 021489-001 Oct 9, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Bracco PROHANCE MULTIPACK gadoteridol INJECTABLE;INJECTION 021489-001 Oct 9, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Bracco PROHANCE MULTIPACK gadoteridol INJECTABLE;INJECTION 021489-001 Oct 9, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Bracco PROHANCE MULTIPACK gadoteridol INJECTABLE;INJECTION 021489-001 Oct 9, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Baxter
Moodys
Accenture
Medtronic
Cipla
Fuji
AstraZeneca
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.